These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8279008)

  • 1. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient.
    Potter JM; Hickman PE; Lynch SV; Henderson A; Wright M; Balderson G; Strong RW
    Transplantation; 1993 Dec; 56(6):1385-8. PubMed ID: 8279008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of the lidocaine-monoethylglycinexylidide test in the liver transplant recipient.
    Potter JM; Hickman PE; Henderson A; Balderson GA; Lynch SV; Strong RW
    Ther Drug Monit; 1996 Aug; 18(4):383-7. PubMed ID: 8857555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of lidocaine metabolism to test liver function during the long-term follow-up of liver transplant recipients.
    Conti F; Dousset B; Cherruau B; Guérin C; Soubrane O; Houssin D; Calmus Y
    Clin Transplant; 2004 Jun; 18(3):235-41. PubMed ID: 15142042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical importance of conventional and quantitative liver function tests in liver transplantation.
    Tanaka E; Inomata S; Yasuhara H
    J Clin Pharm Ther; 2000 Dec; 25(6):411-9. PubMed ID: 11123494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MEGX test: a tool for the real-time assessment of hepatic function.
    Oellerich M; Armstrong VW
    Ther Drug Monit; 2001 Apr; 23(2):81-92. PubMed ID: 11294522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lignocaine metabolism and liver function testing in primary graft failure following orthotopic liver transplantation.
    Potter JM; Wright M; Lynch SV; Strong RW; Henderson A; Balderson G; Walker NI; Hickman PE
    Med J Aust; 1993 Jan; 158(2):125-6. PubMed ID: 8419755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lignocaine metabolite formation as a measure of pre-transplant liver function.
    Oellerich M; Burdelski M; Ringe B; Lamesch P; Gubernatis G; Bunzendahl H; Pichlmayr R; Herrmann H
    Lancet; 1989 Mar; 1(8639):640-2. PubMed ID: 2564460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates.
    Burdelski M; Schütz E; Nolte-Buchholtz S; Armstrong VW; Oellerich M
    Ther Drug Monit; 1996 Aug; 18(4):378-82. PubMed ID: 8857554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute cyclosporine toxicity after liver transplantation is predicted by the lidocaine monoethylglycinexylidide test in the donor.
    Azoulay D; Adam R; Pham P; Salvucci M; Davoll S; Bismuth H; Debuire B; Lemoine A
    Liver Transpl Surg; 1997 Sep; 3(5):526-31. PubMed ID: 9346796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors.
    Zotz RB; von Schönfeld J; Erhard J; Breuer N; Lange R; Beste M; Goebell H; Eigler FW
    Transplantation; 1997 Feb; 63(4):538-41. PubMed ID: 9047147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of lidocaine as a test of liver function in liver transplantation.
    Potter JM; Oellerich M
    Liver Transpl Surg; 1996 May; 2(3):211-24. PubMed ID: 9346651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The unreliability of the lidocaine/monoethylglycinexylidide test for assessment of liver donors.
    Reding R; Wallemacq P; de Ville de Goyet J; Lerut J; Hausleithner V; Feyaerts A; Lambotte L; Otte JB
    Transplantation; 1993 Aug; 56(2):323-6. PubMed ID: 8356585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX).
    Sallie RW; Tredger JM; Williams R
    Biopharm Drug Dispos; 1992 Oct; 13(7):555-8. PubMed ID: 1489946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early assessment of transplanted liver function: lignocaine clearance test (MEGX).
    Freys G; Pottecher T; Calon B; Hamel G; Pain L; Boudjema K; Otteni JC
    Eur J Anaesthesiol; 1997 Jul; 14(4):397-405. PubMed ID: 9253568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence polarization immunoassay and HPLC assays compared for measuring monoethylglycinexylidide in liver-transplant patients.
    Chen Y; Potter JM
    Clin Chem; 1992 Dec; 38(12):2426-30. PubMed ID: 1458579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lignocaine metabolism and MEGX production in the liver transplant donor.
    Potter JM; Hickman PE; Balderson G; Lynch SV; Strong R
    Transplant Proc; 1992 Feb; 24(1):198-9. PubMed ID: 1539243
    [No Abstract]   [Full Text] [Related]  

  • 17. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.
    Oellerich M; Burdelski M; Lautz HU; Schulz M; Schmidt FW; Herrmann H
    Ther Drug Monit; 1990 May; 12(3):219-26. PubMed ID: 2349604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of the in vitro or in vivo monoethylglycinexylidide test for predicting liver graft function.
    Olinga P; Maring JK; Groothuis GM; Kranenburg K; Merema M; Hof IH; Meijer DK; Slooff MJ
    Transplantation; 1997 Jul; 64(1):60-5. PubMed ID: 9233702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors.
    Oellerich M; Schütz E; Polzien F; Ringe B; Armstrong VW; Hartmann H; Burdelski M
    Ther Drug Monit; 1994 Jun; 16(3):225-31. PubMed ID: 8085276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of the donor MEGX test in predicting liver allograft recipient outcome.
    Potter JM; Balderson GA; Hickman PE; Henderson A; Wright M; Burrow B; Lynch SV; Ong TH; Strong RW
    Transplantation; 1994 Aug; 58(4):524-6. PubMed ID: 8073525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.